CA3176234A1 - Methods of treating agitation associated with alzheimer's disease - Google Patents

Methods of treating agitation associated with alzheimer's disease Download PDF

Info

Publication number
CA3176234A1
CA3176234A1 CA3176234A CA3176234A CA3176234A1 CA 3176234 A1 CA3176234 A1 CA 3176234A1 CA 3176234 A CA3176234 A CA 3176234A CA 3176234 A CA3176234 A CA 3176234A CA 3176234 A1 CA3176234 A1 CA 3176234A1
Authority
CA
Canada
Prior art keywords
patient
cmai
score
administering step
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3176234A
Other languages
English (en)
French (fr)
Inventor
Sanjay Dube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3176234A1 publication Critical patent/CA3176234A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3176234A 2020-04-27 2021-04-26 Methods of treating agitation associated with alzheimer's disease Pending CA3176234A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016270P 2020-04-27 2020-04-27
US63/016,270 2020-04-27
PCT/US2021/029246 WO2021222145A1 (en) 2020-04-27 2021-04-26 Methomethods of treating agitation associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
CA3176234A1 true CA3176234A1 (en) 2021-11-04

Family

ID=75914613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3176234A Pending CA3176234A1 (en) 2020-04-27 2021-04-26 Methods of treating agitation associated with alzheimer's disease

Country Status (13)

Country Link
US (1) US20230270738A1 (enExample)
EP (1) EP4142729A1 (enExample)
JP (1) JP2023523373A (enExample)
KR (1) KR20230016636A (enExample)
CN (1) CN115734787A (enExample)
AU (1) AU2021263354A1 (enExample)
BR (1) BR112022021535A2 (enExample)
CA (1) CA3176234A1 (enExample)
IL (1) IL296977A (enExample)
MX (1) MX2022013427A (enExample)
PH (1) PH12022552764A1 (enExample)
TW (1) TW202203922A (enExample)
WO (1) WO2021222145A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
KR20240110812A (ko) * 2021-10-27 2024-07-16 아바니르 파마슈티컬스, 인코포레이티드 알츠하이머병과 관련된 불안을 치료하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US20160143901A1 (en) * 2006-02-03 2016-05-26 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
MX370608B (es) 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
TWI869633B (zh) * 2014-09-14 2025-01-11 美商阿瓦尼爾製藥股份有限公司 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物

Also Published As

Publication number Publication date
EP4142729A1 (en) 2023-03-08
IL296977A (en) 2022-12-01
WO2021222145A1 (en) 2021-11-04
BR112022021535A2 (pt) 2023-01-24
US20230270738A1 (en) 2023-08-31
KR20230016636A (ko) 2023-02-02
TW202203922A (zh) 2022-02-01
WO2021222145A8 (en) 2021-12-30
PH12022552764A1 (en) 2024-03-25
MX2022013427A (es) 2023-01-19
AU2021263354A1 (en) 2022-10-27
JP2023523373A (ja) 2023-06-02
CN115734787A (zh) 2023-03-03

Similar Documents

Publication Publication Date Title
KR102316933B1 (ko) 헌팅턴병 치료를 위한 프리도피딘의 용도
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
US20230270738A1 (en) Methods of treating agitation associated with alzheimer's disease
JP2022524008A (ja) うつ病の治療のためのエスケタミン
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
Raskin et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder
Oslin et al. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
US20230131493A1 (en) Methods of treating agitation associated with alzheimer's disease
JP2024517937A (ja) Ｎｍｄａ受容体拮抗薬の副作用の低減
Haghparast et al. Sedatives and hypnotics
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
WO2024216061A1 (en) Methods of treating depression and anhedonia
WO2024216046A1 (en) Methods of treating anhedonia
CN118510513A (zh) 治疗与阿尔茨海默氏病相关的激越的方法
HK40089955A (en) Methods of treating agitation associated with alzheimer's disease
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
JPWO2014128882A1 (ja) 不安うつ病の治療薬
CA3219829A1 (en) Method of treating essential tremor
Mancano New drugs of 2012, part I

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251014

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260608

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260709